<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02201212</url>
  </required_header>
  <id_info>
    <org_study_id>14-229</org_study_id>
    <secondary_id>CRAD001MUS217T</secondary_id>
    <nct_id>NCT02201212</nct_id>
  </id_info>
  <brief_title>Everolimus for Cancer With TSC1 or TSC2 Mutation</brief_title>
  <official_title>A Phase II Trial of Everolimus for Cancer Patients With Inactivating Mutations in TSC1 or TSC2 or Activating MTOR Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research study, the investigators are evaluating the clinical benefit of everolimus&#xD;
      in cancer patients with inactivating TSC1 or TSC2 mutations or activating MTOR mutations.&#xD;
&#xD;
      This research study is a Phase II clinical trial, which tests the safety and effectiveness of&#xD;
      an investigational drug called everolimus to learn whether the drug works in treating a&#xD;
      specific cancer. &quot;Investigational&quot; means that the drug is being studied. It also means that&#xD;
      the FDA (the U.S. Food and Drug Administration) has not yet approved everolimus for your type&#xD;
      of cancer.&#xD;
&#xD;
      Everolimus is a drug that may stop cancer cells from growing by blocking an important factor&#xD;
      (mTOR) involved in the growth of cells. This drug has been used in treatment for other&#xD;
      cancers and is approved by the Food and Drug Administration for treatment of several types of&#xD;
      cancer, including renal cell carcinoma. Treatment with this drug has been associated with&#xD;
      responses in some patients whose cancers had mutations in TSC1 or TSC2. The investigators&#xD;
      think that patients whose tumors have mutations in TSC1 or TSC2 may have a good chance of&#xD;
      responding to treatment with drugs like everolimus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who fulfill eligibility criteria will be entered into the trial.The participant will&#xD;
      be given a study drug-dosing calendar for each treatment cycle. Each treatment cycle lasts 28&#xD;
      days (4 weeks), during which time the participant will be taking the study drug orally (by&#xD;
      mouth) once daily. The diary will also include special instructions for taking the study&#xD;
      drug. In addition to the administration of the study drugs the participant will be asked to&#xD;
      return to the clinic at various time points so that additional exams can be performed. These&#xD;
      study visits may last as long as 2 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Baseline, Every 8 weeks, 2 Years</time_frame>
    <description>RECIST 1.1 criteria for Objective Response:&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by scan: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Baseline, Every 8 weeks, 2 Years</time_frame>
    <description>Duration of Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Baseline, Up to 2 Years</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>4 Years</time_frame>
    <description>Overall Survival Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Rate</measure>
    <time_frame>2 Years</time_frame>
    <description>CTCAE v4.0 Toxicity Rate Grade 3 or higher</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>TSC1</condition>
  <condition>TSC2</condition>
  <condition>Tuberous Sclerosis Complex</condition>
  <condition>MTOR</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus&#xD;
Fixed doses orally once a day per each 28 day cycle&#xD;
Participants will stay on study as long as they do not progress for a maximum of 24 months.&#xD;
Tumor assessments will be performed after every 2 cycles for as long as they are on study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>Afinitor®</other_name>
    <other_name>Zortress</other_name>
    <other_name>Afinitor Disperz®</other_name>
    <other_name>RAD001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Participants must meet the following criteria on screening examination&#xD;
        to be eligible to participate in the study:&#xD;
&#xD;
          -  Participants must have histologically confirmed advanced malignancy that is either&#xD;
             metastatic and/or unresectable and/or recurrent, with confirmed inactivating mutations&#xD;
             in TSC1 or TSC2, or activating mutations in MTOR, identified in any CLIA-certified&#xD;
             laboratory. All genetic findings must be reviewed by the study PI, Dr. David&#xD;
             Kwiatkowski, prior to study entry.&#xD;
&#xD;
          -  Biopsy of a primary or metastatic lesion must have been performed within the past two&#xD;
             years. Sufficient pathologic material must be available to enable whole exome&#xD;
             sequencing at the time of study entry.&#xD;
&#xD;
          -  Participants must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded) as ≥&#xD;
             20 mm with conventional techniques or as ≥10 mm with spiral CT scan. See section 10&#xD;
             for the evaluation of measureable disease.&#xD;
&#xD;
          -  Participants may have received any number of prior therapies, from 0 to &gt; 10, but&#xD;
             prior treatment with PI3-kinase or mTOR inhibitors is not permitted.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  ECOG performance status &lt;2 (see Appendix A).&#xD;
&#xD;
          -  Participants must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Leukocytes ≥3,000/mcL&#xD;
&#xD;
               -  Absolute neutrophil count ≥1,500/mcL&#xD;
&#xD;
               -  Platelets ≥100,000/mcL&#xD;
&#xD;
               -  Hemoglobin ≥9.0 gr/dL&#xD;
&#xD;
               -  Total bilirubin ≤1.5 ULN&#xD;
&#xD;
               -  AST (SGOT)/ALT (SGPT) ≤ 2.5 X institutional upper limit of normal. Patients with&#xD;
                  confirmed liver metastases are permitted to have AST/ALT at levels ≤ 5X the&#xD;
                  institutional upper limit of normal.&#xD;
&#xD;
               -  Creatinine ≤ 1.5 X the institutional upper limit of normal.&#xD;
&#xD;
               -  Total cholesterol &lt; 300 mg/dL&#xD;
&#xD;
               -  Triglycerides &lt; 250 mg/dL&#xD;
&#xD;
          -  The effects of everolimus on the developing human fetus are unknown. For this reason&#xD;
             and because anti-neoplastic agents are known to be teratogenic, women of child-bearing&#xD;
             potential and men must agree to use adequate contraception (hormonal or barrier method&#xD;
             of birth control; abstinence) prior to study entry and for the duration of study&#xD;
             participation. Should a woman become pregnant or suspect she is pregnant while&#xD;
             participating in this study, she should inform her treating physician immediately.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
          -  Participants who achieve either a partial response or stable disease ≥ 4 months must&#xD;
             agree to undergo a tumor biopsy, if safe and feasible, at the time of progressive&#xD;
             disease while on study drug everolimus.&#xD;
&#xD;
        Exclusion Criteria:Participants who exhibit any of the following conditions at screening&#xD;
        will not be eligible for admission into the study.&#xD;
&#xD;
          -  Participants who have had any of the following:&#xD;
&#xD;
          -  chemotherapy in the previous 2 weeks (6 weeks for nitrosoureas or mitomycin C)&#xD;
&#xD;
          -  radiotherapy within 3 weeks&#xD;
&#xD;
          -  investigational agents within 3 weeks prior to entering the study&#xD;
&#xD;
          -  patients who have not recovered from significant (in the opinion of the investigator)&#xD;
             adverse events due to previous agents administered.&#xD;
&#xD;
          -  Child-Pugh B or C hepatic impairment. Patients with a history of hepatitis or&#xD;
             significant exposure risk should be tested for hepatitis B and C with serologic&#xD;
             markers: HBsAg, HBs Ab, HBcoreIgG Ab, HCV Ab. Patients with active hepatitis B or C&#xD;
             are excluded.&#xD;
&#xD;
          -  Any prior exposure to any PI3 kinase or mTOR inhibitor agent.&#xD;
&#xD;
          -  Participants may not be receiving any other research study agents.&#xD;
&#xD;
          -  Uncontrolled brain or leptomeningeal metastases, including patients who continue to&#xD;
             require glucocorticoids for brain or leptomeningeal metastases. Asymptomatic or&#xD;
             treated brain metastases are acceptable.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to everolimus.&#xD;
&#xD;
          -  A list of prohibited medications on study are listed in Section 5.5&#xD;
&#xD;
          -  Chronic treatment with corticosteroids or other immunosuppressive therapy.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Pregnant women are excluded from this study because everolimus has the potential for&#xD;
             teratogenic or abortifacient effects. Because there is an unknown but potential risk&#xD;
             of adverse events in nursing infants secondary to treatment of the mother with&#xD;
             everolimus, breastfeeding should be discontinued if the mother is treated with&#xD;
             everolimus. These potential risks may also apply to other agents used in this study.&#xD;
&#xD;
          -  Individuals with a recent history of a different malignancy are ineligible except for&#xD;
             the following circumstances: 1) Individuals with a history of other malignancies are&#xD;
             eligible if they have been disease-free for at least 3 years OR are deemed by the&#xD;
             investigator to be at low risk for recurrence of that malignancy; 2) Individuals with&#xD;
             the following cancers are eligible if diagnosed and treated within the past 3 years:&#xD;
             cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.&#xD;
&#xD;
          -  Individuals with known HIV infection are excluded from this study as combination&#xD;
             antiretroviral therapy could potentially result in significant pharmacokinetic&#xD;
             interactions with everolimus. In addition, these individuals are at increased risk of&#xD;
             lethal infections due to the immunosuppressive effects of mTOR inhibition.&#xD;
&#xD;
          -  Patients who have received live attenuated vaccines within 1 week of start of&#xD;
             Everolimus. Patient should also avoid close contact with others who have received live&#xD;
             attenuated vaccines. Examples of live attenuated vaccines include intranasal&#xD;
             influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella and TY21a&#xD;
             typhoid vaccines.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus as defined by HbA1c &gt;8% despite adequate therapy.&#xD;
             Patients with a known history of impaired fasting glucose or diabetes mellitus (DM)&#xD;
             may be included, however blood glucose and antidiabetic treatment must be monitored&#xD;
             closely throughout the trial and adjusted as necessary.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Kwiatkowski, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 23, 2014</study_first_submitted>
  <study_first_submitted_qc>July 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2014</study_first_posted>
  <results_first_submitted>July 27, 2020</results_first_submitted>
  <results_first_submitted_qc>September 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>David Kwiatkowski</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>TSC1</keyword>
  <keyword>TSC2</keyword>
  <keyword>Tuberous Sclerosis Complex</keyword>
  <keyword>MTOR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberous Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02201212/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Everolimus</title>
          <description>Everolimus&#xD;
Fixed doses orally once a day per each 28 day cycle&#xD;
Participants will stay on study as long as they do not progress for a maximum of 24 months.&#xD;
Tumor assessments will be performed after every 2 cycles for as long as they are on study.&#xD;
Everolimus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Everolimus</title>
          <description>Everolimus&#xD;
Fixed doses orally once a day per each 28 day cycle&#xD;
Participants will stay on study as long as they do not progress for a maximum of 24 months.&#xD;
Tumor assessments will be performed after every 2 cycles for as long as they are on study.&#xD;
Everolimus</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" lower_limit="43" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>This is ECOG Performance Status 0 is the best, meaning in very good condition. 4 is the worse, meaning in very poor condition.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate</title>
        <description>RECIST 1.1 criteria for Objective Response:&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by scan: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
        <time_frame>Baseline, Every 8 weeks, 2 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus</title>
            <description>Everolimus&#xD;
Fixed doses orally once a day per each 28 day cycle&#xD;
Participants will stay on study as long as they do not progress for a maximum of 24 months.&#xD;
Tumor assessments will be performed after every 2 cycles for as long as they are on study.&#xD;
Everolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>RECIST 1.1 criteria for Objective Response:&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by scan: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of Response Rate</description>
        <time_frame>Baseline, Every 8 weeks, 2 Years</time_frame>
        <population>Subjects with Partial Response</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus</title>
            <description>Everolimus&#xD;
Fixed doses orally once a day per each 28 day cycle&#xD;
Participants will stay on study as long as they do not progress for a maximum of 24 months.&#xD;
Tumor assessments will be performed after every 2 cycles for as long as they are on study.&#xD;
Everolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of Response Rate</description>
          <population>Subjects with Partial Response</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="4.8" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>Baseline, Up to 2 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus</title>
            <description>Everolimus&#xD;
Fixed doses orally once a day per each 28 day cycle&#xD;
Participants will stay on study as long as they do not progress for a maximum of 24 months.&#xD;
Tumor assessments will be performed after every 2 cycles for as long as they are on study.&#xD;
Everolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.4" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall Survival Rate</description>
        <time_frame>4 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus</title>
            <description>Everolimus&#xD;
Fixed doses orally once a day per each 28 day cycle&#xD;
Participants will stay on study as long as they do not progress for a maximum of 24 months.&#xD;
Tumor assessments will be performed after every 2 cycles for as long as they are on study.&#xD;
Everolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall Survival Rate</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.27" lower_limit="0.43" upper_limit="39.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Rate</title>
        <description>CTCAE v4.0 Toxicity Rate Grade 3 or higher</description>
        <time_frame>2 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus</title>
            <description>Everolimus&#xD;
Fixed doses orally once a day per each 28 day cycle&#xD;
Participants will stay on study as long as they do not progress for a maximum of 24 months.&#xD;
Tumor assessments will be performed after every 2 cycles for as long as they are on study.&#xD;
Everolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Rate</title>
          <description>CTCAE v4.0 Toxicity Rate Grade 3 or higher</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months after study discontinuation, up to 5 years</time_frame>
      <desc>National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v4.0)</desc>
      <group_list>
        <group group_id="E1">
          <title>Everolimus</title>
          <description>Everolimus&#xD;
Fixed doses orally once a day per each 28 day cycle&#xD;
Participants will stay on study as long as they do not progress for a maximum of 24 months.&#xD;
Tumor assessments will be performed after every 2 cycles for as long as they are on study.&#xD;
Everolimus</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>any adverse event per CTCAE v4.0</sub_title>
                <description>any adverse event per CTCAE v4.0</description>
                <counts group_id="E1" events="100" subjects_affected="20" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Kwiatkowski</name_or_title>
      <organization>Dana Farber Cancer Institute</organization>
      <phone>8573070781</phone>
      <email>dk@rics.bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

